Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07534592 | A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | PHASE1 | RECRUITING | 40 | — | — | Apr 16, 2026 | Sep 18, 2026 | May 12, 2026 | 2 | United States |
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
| Arm | Type | Description |
|---|---|---|
| Group 1: Period 1 | EXPERIMENTAL | Participants will receive a single dose of atorvastatin on Day 1. |
| Group 1: Period 2 | EXPERIMENTAL | Participants will receive single dose of atorvastatin on Day 5 and then receive multiple doses of elecoglipron from Day 7 to Day 40. |
| Group 1: Period 3 | EXPERIMENTAL | Participants will receive single dose of atorvastatin on Day 41 and then receive multiple doses of elecoglipron from Day 41 to Day 43. |
| Group 1: Period 4 | EXPERIMENTAL | Participants will receive elecoglipron in the morning and a single dose of atorvastatin in the evening on Day 44. Participant will continue elecoglipron on Day 45. Participants will receive daily administration of different doses of elecoglipron alone from Day 46 to Day 58. |
| Group 1: Period 5 | EXPERIMENTAL | Participants will receive single dose of atorvastatin and elecoglipron on Day 59. Participants will receive elecoglipron alone on Day 60 to Day 61. |
| Group 1: Period 6 | EXPERIMENTAL | Participants will receive elecoglipron in the morning and a single dose of atorvastatin in the evening on Day 62. Participant will continue elecoglipron alone from Day 63 to Day 64. |
| Group 2: Period 1 | EXPERIMENTAL | Participants will receive single dose of rosuvastatin on Day 1 and then multiple doses of elecoglipron from Day 5 to Day 38. |
| Group 2: Period 2 | EXPERIMENTAL | Participants will receive elecoglipron in the morning along with a single dose of rosuvastatin on Day 39. Participant will continue elecoglipron alone from Day 40 to Day 44. |
| Group 2: Period 3 | EXPERIMENTAL | Participants will receive elecoglipron in the morning and a single dose of rosuvastatin in the evening on Day 45. Participant will continue on different doses of elecoglipron alone from Day 46 to Day 59. |
| Group 2: Period 4 | EXPERIMENTAL | Participants will receive elecoglipron in the morning along with a single dose of rosuvastatin on Day 60. Participant will continue elecoglipron alone from Day 61 to Day 65. |
| Group 2: Period 5 | EXPERIMENTAL | Participants will receive elecoglipron in the morning and a single dose of rosuvastatin in the evening on Day 66. Participant will continue on elecoglipron alone from Day 67 to Day 69. |
| Name | Type | Description |
|---|---|---|
| Elecoglipron | DRUG | Elecoglipron will be administered as oral tablet. |
| Atorvastatin | DRUG | Atorvastatin will be administered as oral tablet. |
| Rosuvastatin | DRUG | Rosuvastatin will be administered as oral tablet. |
Inclusion Criteria: * All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit. * Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception througho...